Global week ahead: Trump’s Nobel dreams meet economic reality

Global week ahead: Trump’s Nobel dreams meet economic reality


In this day and age, receiving a cold call at any time can be disarming, but Norway’s finance minister reportedly took a most surprising ring on the streets of Oslo earlier this month.

According to Norwegian newspaper Dagens Naeringsliv, the cold caller was U.S. President Donald Trump, and the request for Norway’s Finance Minister Jens Stoltenberg, was how the American leader could be nominated for a Nobel Peace Prize.

Trump has been publicly explicit about his desire to be awarded the prize, which some say is a driving factor behind his efforts to broker a peace deal for Ukraine and Russia, as well as his focus on Israel and Gaza.

But in June he took to Truth Social to complain: “No, I won’t get a Nobel Peace Prize no matter what I do, including Russia/Ukraine, and Israel/Iran, whatever those outcomes may be, but the people know, and that’s all that matters to me!”

This week, it will be Trump’s impact on the economy that will be in focus, as the group of Nobel Laureates that he seemingly hopes to join will meet for their annual event in Lindau, Germany.

It could make for uncomfortable listening for the White House, with one of the most famous Nobel prize-winning economists, Joseph Stiglitz telling The Guardian that “the U.S. has become, I would say, a scary place to invest.” The administration’s tariff policy risks triggering stagflation in a move that is making the Federal Reserve “clearly worried,” Stiglitz said earlier this year.

President Trump, Ukrainian President Zelenskyy, and European Union leaders meet at White House

Nobel Laureate Roger Myerson, who is also attending the event in Lindau, is more concerned by American politics, writing in an opinion piece for The Hill that “when large groups of voters have become convinced that only one party really cares about them, then they may feel no stake in democracy itself… and support their leader in shaking off its inconvenient constitutional restraints.”

Meanwhile, Nobel Laureate Simon Johnson has also voiced his concerns about American isolationism, telling the Nobel Prize Conversations podcast that it is “…destroying human capital and handing a massive advantage to geopolitical competitors. It’s a self-defeating foolish action by the Trump administration.”

It’s a tough crowd for President Trump. He does have one unlikely supporter in his bid for the peace prize though. Former Democratic rival and First Lady Hillary Clinton recently said if he could end the war between Ukraine and Russia “without putting Ukraine in a position where it must concede its territory to the aggressor… I’d nominate him for a Nobel Peace Prize.”

CNBC will speak live to Nobel Laureates from the meeting in Lindau on Wednesday and Thursday, tune in to hear their views.



Source

Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’
World

Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’

Howard Marks warned that investors hunting for bargains may be disappointed, saying markets are still far from distressed levels despite bouts of volatility. The co-founder and co-chairman of Oaktree Capital Management, who famously foresaw the dot-com bubble, said the current environment reflects an ongoing “tug of war” between bullish and bearish forces, with optimism largely […]

Read More
Investors are misreading news about the Iran war, analysts say as markets whipsaw
World

Investors are misreading news about the Iran war, analysts say as markets whipsaw

An Iranian flag flutters as a woman walks past damaged buildings amid a 10-day ceasefire between Lebanon and Israel, in the southern suburbs of Beirut, Lebanon, April 20, 2026. Marko Djurica | Reuters “Complacent” investors risk getting wrong-footed as they continue to misread developments in the Iran war, analysts said after markets reacted to the […]

Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to  billion
World

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]

Read More